Accessibility Menu
 
Candel Therapeutics logo

Candel Therapeutics

(NASDAQ) CADL

Current Price$6.48
Market Cap$476.10M
Since IPO (2021)-7%
5 YearN/A
1 Year+30%
1 Month+30%

Candel Therapeutics Financials at a Glance

Market Cap

$476.10M

Revenue (TTM)

$0.00

Net Income (TTM)

$38.18M

EPS (TTM)

$-0.70

P/E Ratio

-9.27

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$6.48

Volume

72,443

Open

$7.05

Previous Close

$6.48

Daily Range

$6.40 - $7.05

52-Week Range

$4.34 - $7.66

CADL News

CADL: Motley Fool Moneyball Superscore

45

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Candel Therapeutics

Industry

Biotechnology

Employees

55

CEO

Paul-Peter Tak, MD, PhD

Headquarters

Needham, MA 02494, US

CADL Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-65%

Return on Capital

-42%

Return on Assets

-30%

Earnings Yield

-10.79%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$476.10M

Shares Outstanding

73.25M

Volume

72.44K

Short Interest

0.00%

Avg. Volume

1.38M

Financials (TTM)

Gross Profit

$845.00K

Operating Income

$48.27M

EBITDA

$47.42M

Operating Cash Flow

$38.31M

Capital Expenditure

$587.00K

Free Cash Flow

$38.90M

Cash & ST Invst.

$119.73M

Total Debt

$1.90M

Candel Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$163.00K

+33.5%

Gross Margin

0.00%

N/A

Market Cap

$476.10M

N/A

Market Cap/Employee

$12.53M

N/A

Employees

38

N/A

Net Income

$29.50M

-109.6%

EBITDA

$40.12M

-198.6%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$117.83M

+32.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$1.46M

-51.5%

Short Term Debt

$445.00K

-95.7%

Return on Assets

-30.50%

N/A

Return on Invested Capital

-41.54%

N/A

Free Cash Flow

$10.98M

-88.7%

Operating Cash Flow

$10.57M

-81.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CTNMContineum Therapeutics, Inc. Class A Common Stock
$12.41-0.08%
KYTXKyverna Therapeutics, Inc.
$9.06+1.23%
EDITEditas Medicine, Inc.
$2.91-9.35%
CABACabaletta Bio, Inc.
$2.95-3.28%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$82.54+0.24%
NVDANvidia
$208.27+0.04%
NOKNokia
$10.46+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.17+0.01%

Questions About CADL

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.